Overview

Founded in 1998, Rubicon Genomics is dedicated to the research, development and commercialization of technologies and applications that further the understanding of the human genome and its application in personalized medicine. The company’s primary technology speeds the analysis of DNA by reformatting chromosomes.

Rubicon’s OmniPlex Technology reformats chromosomes into molecular units called Plexisomes that can represent the entire genome in equal lengths of amplifiable DNA. Rubicon’s processing of these Plexisomes are designed to break the PCR bottleneck by enabling highly effective multiplexing and sample amplification. The company’s PENT (Polymerase Extension Nick Translation) sequencing is designed to increase read length and reliability of sequencing reactions.

OmniPlex serves as a platform for a revenue-generating business in the existing markets of human, plant, animal and microorganism genomic research. As the industry matures, OmniPlex is aiming to enable personalized medicine on the molecular level by making patient-specific treatment decisions commercially viable.

Partners

The company had not announced any formation of collaborations or partnerships.